Literature DB >> 21112078

Is older age a poor prognostic factor in stage I and II endometrioid endometrial adenocarcinoma?

Nicole D Fleming1, Scott E Lentz, Ilana Cass, Andrew J Li, Beth Y Karlan, Christine S Walsh.   

Abstract

OBJECTIVE: Prior studies have shown that age ≥70 years is associated with more aggressive non-endometrioid histology and worse survival in endometrial cancer. The purpose of this study is to assess if age is an independent poor prognostic factor in endometrioid histologies.
METHODS: Under an IRB-approved protocol, we identified patients with surgical stage I to II endometrioid endometrial adenocarcinoma from 1995 to 2008 at two institutions. Patients were divided into two groups based on age at diagnosis: Group A (age 50-69 years) and Group B (age≥70 years). All patients underwent hysterectomy, bilateral salpingoophorectomy, +/-pelvic/aortic lymphadenectomy and adjuvant therapy. Prognostic factors were evaluated by univariate and multivariate analyses.
RESULTS: We identified 338 patients with stage IA to IIB endometrioid endometrial adenocarcinoma. The median age in Group A was 59 years (range 50-69) and Group B was 75 years (range 70-92). Patients in Group B were more likely to have hypertension (51% vs. 68%, p=0.006) and coronary artery disease (9% vs. 18%, p=0.03). There were no differences in progression-free or disease-specific survival, however, Group B had a worse overall survival (OS) (50.1 vs. 62.6 months, p=0.03). On univariate analysis, age (p=0.04), grade (p=0.006), and coronary artery disease (p=0.01) were associated with worse OS. After adjusting for grade and coronary artery disease, age was no longer a significant variable for OS (p=0.17).
CONCLUSIONS: After adjusting for other poor prognostic factors, age ≥70 years alone may not be a significant variable affecting overall survival in patients with early stage endometrioid endometrial adenocarcinoma.
Copyright © 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 21112078     DOI: 10.1016/j.ygyno.2010.10.038

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  6 in total

1.  Frailty measure is more predictive of outcomes after curative therapy for endometrial cancer than traditional risk factors in women 60 and older.

Authors:  Jane A Driver; Akila N Viswanathan
Journal:  Gynecol Oncol       Date:  2017-03-28       Impact factor: 5.482

2.  The preoperative G8 geriatric screening tool independently predicts survival in older patients with endometrial cancer: results of a retrospective single-institution cohort study.

Authors:  Katharina Anic; Christin Altehoefer; Slavomir Krajnak; Mona Wanda Schmidt; Roxana Schwab; Valerie Catherine Linz; Marcus Schmidt; Christiane Westphalen; Erik Kristoffer Hartmann; Annette Hasenburg; Marco Johannes Battista
Journal:  J Cancer Res Clin Oncol       Date:  2022-02-25       Impact factor: 4.553

3.  Feasibility study of pelvic helical IMRT for elderly patients with endometrial cancer.

Authors:  Jean-Emmanuel Bibault; Philippe Nickers; Emmanuelle Tresch; Abel Cordoba; Eric Leblanc; Pauline Comte; Thomas Lacornerie; Eric Lartigau
Journal:  PLoS One       Date:  2014-11-25       Impact factor: 3.240

4.  Risk group criteria for tailoring adjuvant treatment in patients with endometrial cancer: a validation study of the Gynecologic Oncology Group criteria.

Authors:  Tae Wook Kong; Suk Joon Chang; Jiheum Paek; Yonghee Lee; Mison Chun; Hee Sug Ryu
Journal:  J Gynecol Oncol       Date:  2014-11-03       Impact factor: 4.401

5.  Preponderance of endometrial carcinoma in elderly patients.

Authors:  Naoki Ogane; Shin-Ichi Hori; Mitsutake Yano; Tomomi Katoh; Shingo Kamoshida; Hisamori Kato; Yoichi Kameda; Masanori Yasuda
Journal:  Mol Clin Oncol       Date:  2018-07-19

Review 6.  Age Is Not a Limiting Factor in Interventional Radiotherapy (Brachytherapy) for Patients with Localized Cancer.

Authors:  Valentina Lancellotta; György Kovács; Luca Tagliaferri; Elisabetta Perrucci; Giuseppe Colloca; Vincenzo Valentini; Cynthia Aristei
Journal:  Biomed Res Int       Date:  2018-01-21       Impact factor: 3.411

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.